keyword
MENU ▼
Read by QxMD icon Read
search

rasagiline

keyword
https://www.readbyqxmd.com/read/27833522/histamine-h3-receptors-and-its-antagonism-as-a-novel-mechanism-for-antipsychotic-effect-a-current-preclinical-clinical-perspective
#1
REVIEW
Danish Mahmood
Histamine H3 receptors are present as autoreceptors on histaminergic neurons and as heteroreceptors on nonhistaminergic neurones. They control the release and synthesis of histamine and several other key neurotransmitters in the brain. H3 antagonism may be a novel approach to develop a new class of antipsychotic medications given the gathering evidence reporting therapeutic efficacy in several central nervous system disorders. Several medications such as cariprazine, lurasidone, LY214002, bexarotene, rasagiline, raloxifene, BL-1020 and ITI-070 are being developed to treat the negative symptoms and cognitive impairments of schizophrenia...
October 2016: International Journal of Health Sciences
https://www.readbyqxmd.com/read/27829318/cognitive-effects-of-rasagiline-in-mild-to-moderate-stage-parkinson-s-disease-without-dementia
#2
Laura L Frakey, Joseph H Friedman
The authors studied the effects of rasagiline on cognition in a sample of 50 nondemented patients with mild to moderate Parkinson's disease (PD) using a double-blind, placebo controlled design. Cognition and motor symptoms were assessed at baseline and after 6 months of receiving either rasagiline or placebo. Participants receiving rasagiline showed improvement in their motor symptoms of PD compared to participants receiving placebo. No significant changes in performance on neuropsychological measures of cognition were observed between the groups...
November 10, 2016: Journal of Neuropsychiatry and Clinical Neurosciences
https://www.readbyqxmd.com/read/27827298/open-label-study-of-sleep-disturbances-in-patients-with-parkinson-s-disease-treated-with-rasagiline
#3
Michel Panisset, Jean-Louis Stril, Manon Bélanger, Geneviève Lehoux, Donna Coffin, Sylvain Chouinard
BACKGROUND: The prevalence of sleep disturbances among patients with Parkinson's disease (PD) is estimated to occur in 37% to 98% of patients. Sleep disturbances have been associated with a reduced quality of life for patients with PD. The objective of this study was to assess the impact of rasagiline treatment on the severity of sleep disturbances among patients with idiopathic PD. METHODS: In this open-label, multicentre study, 110 adult patients with idiopathic PD were treated with rasagiline either as monotherapy or as adjunct therapy...
November 2016: Canadian Journal of Neurological Sciences. le Journal Canadien des Sciences Neurologiques
https://www.readbyqxmd.com/read/27803666/inhibitors-of-mao-a-and-mao-b-in-psychiatry-and-neurology
#4
REVIEW
John P M Finberg, Jose M Rabey
Inhibitors of MAO-A and MAO-B are in clinical use for the treatment of psychiatric and neurological disorders respectively. Elucidation of the molecular structure of the active sites of the enzymes has enabled a precise determination of the way in which substrates and inhibitor molecules are metabolized, or inhibit metabolism of substrates, respectively. Despite the knowledge of the strong antidepressant efficacy of irreversible MAO inhibitors, their clinical use has been limited by their side effect of potentiation of the cardiovascular effects of dietary amines ("cheese effect")...
2016: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/27729794/rasagiline-for-sleep-disorders-in-patients-with-parkinson-s-disease-a-prospective-observational-study
#5
Carla Schettino, Clemente Dato, Guglielmo Capaldo, Simone Sampaolo, Giuseppe Di Iorio, Mariarosa Ab Melone
INTRODUCTION: Rasagiline is a selective, irreversible monoamine oxidase B inhibitor that ameliorates the symptoms of Parkinson's disease (PD) by inhibiting striatal dopamine metabolism. There is also evidence that monoamine oxidase B inhibitors increase melatonin levels in the pineal gland and may have a beneficial effect on sleep disorders, which are a common feature in patients with PD. METHODS: This single-center, prospective, observational, 12-week study compared the effect of combination therapy with levodopa 200-300 mg/d + rasagiline 1 mg/d (n=19) with levodopa 200-300 mg/d alone (n=19) in the treatment of sleep disorders in patients with idiopathic PD...
2016: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/27715253/an-overview-of-analytical-methods-for-the-determinationof-monoamine-oxidase-inhibitors-in-pharmaceutical-formulations-and-biological-fluids
#6
Cafer Saka
Monoamine oxidase inhibitors (MAOIs) were the first type of antidepressant developed. MAOIs elevate the levels of norepinephrine, serotonin, and dopamine by inhibiting an enzyme called monoamine oxidase. They are also used in the treatment of Parkinson's disease, tuberculosis, and several other disorders. Therefore, it is very important to develop efficient analytical methods for monitoring and management. There are two isoforms of monoamine oxidase, MAO-A and MAO-B. In this article, analyses of MAOIs in pharmaceutical formulations and biological fluids were reviewed from 2000 to the present, including all types of chromatographic, spectrophotometric, electrophoretic, and voltammetric techniques, focusing on isoniazid, tranylcypromine, moclobemide, rasagiline, and selegiline...
October 7, 2016: Critical Reviews in Analytical Chemistry
https://www.readbyqxmd.com/read/27651784/no-synergism-between-bis-propyl-cognitin-and-rasagiline-on-protecting-dopaminergic-neurons-in-parkinson-s-disease-mice
#7
Cheng-You Zheng, Bao-Jian Guo, Wei Cai, Wei Cui, Shing-Hung Mak, Yu-Qiang Wang, Simon Ming-Yuen Lee, Yi-Fan Han, Zai-Jun Zhang
Rasagiline, a monoamine oxidase-B inhibitor, and bis(propyl)-cognitin (B3C), a novel dimer are reported to be neuroprotective. Herein, the synergistical neuroprotection produced by rasagiline and B3C was investigated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice of Parkinsonism. By using neurobehavioural tests, high-performance liquid chromatography and western blot assay, we showed that B3C at 0.3 mg/kg, rasagiline at 0.02 mg/kg, as well as co-treatment with B3C and rasagiline prevented MPTP-induced behavioural abnormities, increased the concentrations of dopamine and its metabolites in the striatum, and up-regulated the expression of tyrosine hydroxylase in the substantia nigra...
August 2016: Neural Regeneration Research
https://www.readbyqxmd.com/read/27618783/patterns-and-predictors-of-freezing-of-gait-improvement-following-rasagiline-therapy-a-pilot-study
#8
Fariborz Rahimi, Angela C Roberts, Mandar Jog
OBJECTIVES: Freezing of gait (FoG) is a challenging clinical symptom in Parkinson's disease with variable improvements in FoG with rasagiline. In this prospective, uncontrolled, pre-/post- treatment pilot study, we explore the clinical variables that contribute to this variability and those that predict improvement. PATIENTS AND METHODS: Frequency and duration of FoG, along with other standardized scales, were evaluated in 18 optimally medicated PD participants with intractable FoG, prior to and after completion of a 90-day course of 1mg daily rasagiline...
November 2016: Clinical Neurology and Neurosurgery
https://www.readbyqxmd.com/read/27503749/a-spectrophotometric-assay-for-monoamine-oxidase-activity-with-2-4-dinitrophenylhydrazine-as-a-derivatized-reagent
#9
Guili Huang, Fei Zhu, Yuhang Chen, Shiqiang Chen, Zhonghong Liu, Xin Li, Linlin Gan, Li Zhang, Yu Yu
A simple, rapid and reliable spectrophotometry was developed to determine monoamine oxidase (MAO). In this study, 2,4-dinitrophenylhydrazine (DNPH), a classic derivatizing reagent, was used to detect MAO-dependent aldehyde production; and traditional DNPH spectrophotometry was simplified. Benzylamine and serotonin oxidation were catalyzed by MAO-B and MAO-A, respectively, to aldehydes. These were derivatized with DNPH, and the corresponding quinones were further formed by adding NaOH. These DNPH derivatives with large conjugated structures were directly measured spectrophotometrically at 465 nm and 425 nm, without the need for precipitating, washing and suspending procedures...
November 1, 2016: Analytical Biochemistry
https://www.readbyqxmd.com/read/27474888/minimally-clinically-important-decline-in-the-parkinsonian-variant-of-multiple-system-atrophy
#10
Florian Krismer, Klaus Seppi, Gregor K Wenning, Victor Abler, Spyridon Papapetropoulos, Werner Poewe
INTRODUCTION: We provide the first characterization of the minimally clinically important difference on the Unified Multiple System Atrophy Rating Scale in patients with the parkinsonian variant of early MSA. METHODS: Data from a randomized controlled trial of rasagiline were analyzed using clinical global impression as an anchor. Because too few patients improved with treatment, analyses were limited to defining scale cutoffs that discriminated between minimal worsening and no change...
October 2016: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/27465906/is-it-possible-to-achieve-bio-equivalence-between-an-oral-solid-immediate-release-and-an-analogue-enteric-coated-formulation
#11
Dannit Licht, Rachel Cohen, Ofer Spiegelstein, Laura Rabinovich-Guilatt, Marina Zholkovsky, Adrian Gilbert, Jennifer B Dressman, Muhammad Safadi
OBJECTIVES: While bioequivalence between enteric-coated and immediate-release formulations can be achieved in terms of AUC, gastric emptying of enteric-coated dosage forms is a stochastic event, usually leading to lower Cmax values than those observed with the corresponding immediate release. This article examines challenges of developing enteric-coated dosage forms which are bioequivalent to the corresponding immediate-release formulations in terms of both AUC and Cmax using rasagiline as a model compound...
October 2016: Journal of Pharmacy and Pharmacology
https://www.readbyqxmd.com/read/27438181/comparison-of-selegiline-and-rasagiline-therapies-in-parkinson-disease-a-real-life-study
#12
Chava Peretz, Hagar Segev, Violet Rozani, Tanya Gurevich, Baruch El-Ad, Judith Tsamir, Nir Giladi
BACKGROUND: We aimed to compare indicators of Parkinson disease (PD) progression between patients first prescribed either selegiline or rasagiline as their antiparkinsonian drugs (APDs) on the basis of real-life data. METHODS: Pharmacy data on members of a large Israeli health maintenance organization, treated as patients with PD during 2001-2012 and prescribed selegiline or rasagiline as their first APD, were analyzed. The first APD was selegiline for 349 patients (2001-2006) and rasagiline for 485 patients (2007-2012)...
September 2016: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/27431201/long-term-effects-of-rasagiline-and-the-natural-history-of-treated-parkinson-s-disease
#13
Olivier Rascol, Robert A Hauser, Fabrizio Stocchi, Cheryl J Fitzer-Attas, Yulia Sidi, Victor Abler, C Warren Olanow
BACKGROUND: The Attenuation of Disease progression with Azilect GIven Once-daily (ADAGIO) delayed-start study demonstrated a benefit of early-start treatment with rasagiline 1 mg/day versus delayed-start treatment in PD. This follow-up study aimed to assess whether these benefits persist and the clinical progression rate during long-term naturalistic treatment. METHODS: The ADAGIO Follow-Up study was initiated approximately 26 months after completion of the ADAGIO study...
July 19, 2016: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/27386592/-comorbid-states-in-parkinson-s-disease-an-effect-of-mao-b-inhibitors
#14
N V Titova, E A Katunina, N N Sotnikova
The comorbidity in Parkinson's disease (PD), which is closely related to the tolerability of antiparkinsonian drugs, is-'analyzed. The authors present the results of the studies that have confirmed the greater safety of rasagiline compared to dopamine receptor agonists in elderly patients. The effects of rasagiline, including combinations of this drug with antidepressants, on-depression in PD and the low risk,of the serotonin -syndrome caused by these combinations are considered. The studies demonstrated the effect of rasagiline on fatigue and cognitive functions in PD patients are described...
2016: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/27318273/design-synthesis-and-evaluation-of-novel-dual-monoamine-cholinesterase-inhibitors-as-potential-treatment-for-alzheimer-s-disease
#15
Wei Liu, Ming Lang, Moussa B H Youdim, Tamar Amit, Yewei Sun, Zaijun Zhang, Yuqiang Wang, Orly Weinreb
Current novel therapeutic approach suggests that multifunctional compounds with diverse biological properties and a single bioavailability and pharmacokinetic metabolism, will produce higher significant advantages in treatment of neurodegenerative diseases, such as Alzheimer's disease (AD). Based on this rational, a new class of cholinesterase (ChE)-monoamine oxidase (MAO) inhibitors were designed and synthesized by amalgamating the propargyl moiety of the irreversible selective MAO-B inhibitor, neuroprotective/neurorestorative anti-Parkinsonian drug, rasagiline, into the "N-methyl" position of the ChE inhibitor, anti-AD drug rivastigmine...
October 2016: Neuropharmacology
https://www.readbyqxmd.com/read/27272586/treatment-of-fatigue-in-parkinson-disease
#16
COMMENT
Roy G Elbers, Henk W Berendse, Gert Kwakkel
CLINICAL QUESTION: Which pharmacological and nonpharmacological interventions are associated with improvement in general, physical, or mental fatigue and minimal adverse effects in patients with Parkinson disease (PD)? BOTTOM LINE: Rasagiline, modafinil, and doxepin are associated with improvement in fatigue and are not associated with increased risk of adverse effects in patients with PD. However, the quality of evidence is limited and does not provide a clear basis for treatment decisions...
June 7, 2016: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/27259485/effects-of-anti-depressant-treatments-on-fadd-and-p-fadd-protein-in-rat-brain-cortex-enhanced-anti-apoptotic-p-fadd-fadd-ratio-after-chronic-desipramine-and-fluoxetine-administration
#17
M Julia García-Fuster, Jesús A García-Sevilla
RATIONALE: Fas-associated death domain (FADD) is an adaptor of death receptors that can also induce anti-apoptotic actions through its phosphorylated form (p-FADD). Activation of monoamine receptors, indirect targets of classic anti-depressant drugs (ADs), reduced FADD and increased p-FADD and p-FADD/FADD ratio in brain. OBJECTIVES: To ascertain whether ADs, which indirectly regulate monoamine receptors, modulate FADD protein forms to promote anti-apoptotic actions...
August 2016: Psychopharmacology
https://www.readbyqxmd.com/read/27256636/parkinson-disease-dopamine-receptor-variants-improve-response-to-rasagiline-in-pd
#18
Ian Fyfe
No abstract text is available yet for this article.
July 2016: Nature Reviews. Neurology
https://www.readbyqxmd.com/read/27230855/prospera-a-randomized-controlled-trial-evaluating-rasagiline-in-progressive-supranuclear-palsy
#19
Georg Nuebling, Mira Hensler, Sabine Paul, Andreas Zwergal, Alexander Crispin, Stefan Lorenzl
To date, pharmacological treatment options for progressive supranuclear palsy (PSP), a neurodegenerative tauopathy, are limited. The MAO-B inhibitor rasagiline has shown neuroprotective effects in preclinical models of neurodegeneration. To evaluate the safety, tolerability and therapeutic effect of rasagiline on symptom progression in PSP. In this 1-year randomized, double-blind, placebo-controlled trial, 44 patients fulfilling the NINDS-PSP criteria were randomized to 1 mg/d rasagiline or placebo. The combined primary endpoint included symptom progression as measured by the PSP rating scale (PSP-RS) and the requirement of L-dopa rescue medication...
August 2016: Journal of Neurology
https://www.readbyqxmd.com/read/27220335/3-4-dihydroxyphenylethanol-hydroxytyrosol-mitigates-the-increase-in-spontaneous-oxidation-of-dopamine-during-monoamine-oxidase-inhibition-in-pc12-cells
#20
David S Goldstein, Yunden Jinsmaa, Patti Sullivan, Courtney Holmes, Irwin J Kopin, Yehonatan Sharabi
The catecholaldehyde hypothesis predicts that monoamine oxidase (MAO) inhibition should slow the progression of Parkinson's disease, by decreasing production of the autotoxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL). Inhibiting MAO, however, diverts the fate of cytoplasmic dopamine toward potentially harmful spontaneous oxidation products, indicated by increased 5-S-cysteinyl-dopamine (Cys-DA) levels. 3,4-Dihydroxyphenylethanol (hydroxytyrosol) is an abundant anti-oxidant phenol in constituents of the Mediterranean diet...
September 2016: Neurochemical Research
keyword
keyword
100957
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"